title: Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report.
abstract: BACKGROUND
  Recent research demonstrated that vitamin D, apart from calcium-related actions, has antiproliferative, prodifferentia-tive and immunomodulatory activities.
  
  
  OBJECTIVE
  To determine whether actinic keratoses may benefit from the antiproliferative and prodifferentiative effects of topical vitamin D.
  
  
  METHODS
  The study was an investigator-blinded, half-side comparison trial. Patients applied calcipotriol cream to one side and Ultrabase cream as placebo to the other side of the scalp and/or face for 12 weeks. The total number of actinic keratoses (AKs), diameters and total scores of the target lesions were determined at each visit.
  
  
  RESULTS
  Nine patients were included, eight of whom completed the treatment. There was a statistically significant difference between the total number of AKs at baseline and at week 12 on calcipotriol applied side whereas no difference was detected on placebo applied side (p = 0.028 vs p = 1.00). The mean total score of the target lesions reduced significantly at week 12 on calcipotriol side; however, no significant reduction was found on placebo side (p = 0.017 vs p = 0.056). Although side effects were more common on calcipotriol side, the difference was not statistically significant.
  
  
  CONCLUSIONS
  Topical calcipotriol may show promise in the treatment of actinic keratoses. More studies are needed to confirm its efficacy.
authors.affiliation: Marmara University School of Medicine, Department of Dermatology, Istanbul,Turkey. seckin_dilek@yahoo.com
authors.forename: Dilek
authors.initials: D
authors.lastname: Seckin
authors.forename: Asli Aksu
authors.initials: AA
authors.lastname: Cerman
authors.forename: Ayfer
authors.initials: A
authors.lastname: Yildiz
authors.forename: Tulin
authors.initials: T
authors.lastname: Ergun
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method
chemical_list: D003879:Dermatologic Agents; C055085:calcipotriene; D002117:Calcitriol